Selling, and administrative expenses for the Q1 of 2023 were $113,000,000 compared to 96,000,000 in the Q1 of 2022. The increase is related to expansion of our commercial sales operations in Europe and commercial investment in preparation for the fall 2023 vaccination campaign, partially offset by certain cost containment measures to reduce our operating spend. For the Q1 of 2023, we recorded a net loss of $294,000,000 compared to net income of $203,000,000 in the Q1 of 2022, again reflecting the emerging seasonality of our business. Please turn to Slide 25. In addition to making great strides to reduce the rate of spend during the Q1 of 2023, We also made significant progress to reduce our outstanding current liabilities from $2,500,000,000 to 1,900,000,000 The $541,000,000 decrease, including funding of the maturity of the 3 During April 2023, we addressed additional liabilities totaling 140,000,000 Supportive of funding this April activity is $100,000,000 payment to Novavax secured for the Q2 of As of March 31, 2023, the $858,000,000 of their current liabilities balance includes Approximately $700,000,000 related to the ongoing GAFI arbitration and $113,000,000 related to a 2023 UK APA payment.